The Inhibitory Effects of Trastuzumab on Corneal Neovascularization

American Journal of Ophthalmology

Volumn 147, Issue 4, 2009, Pages

  Güler, Mete ^a   Yilmaz, Turgut ^a   Özercan, Ibrahim ^a   Elkiran, Tamer ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG INHIBITION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STROMA; VISUAL ACUITY;

EID: 62649156293     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.09.022     Document Type: Article

References (39)

1. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
2. Chang J.H., Gabison E.E., Kato T., and Azar D.T. Corneal neovascularization. Curr Opin Ophthalmol 12 (2001) 242-249
3. Mendelsohn A.D., Lo G.G., and Stock E.L. Laser photocoagulation of feeder vessels in lipid keratopathy. Ophthalmic Surg 17 (1986) 502-508
4. Goto S. Q-switched Nd:YAG laser treatment for corneal neovascularization. Jpn J Ophthalmol 36 (1992) 291-300
5. BenEzra D., Griffin B.W., Maftzir G., Sharif N.A., and Clark A.F. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38 (1997) 1954-1962
6. Benelli U., Bocci G., Danesi R., et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res 67 (1998) 133-142
7. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
8. Bocci G., Danesi R., Benelli U., et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 43 (1999) 205-212
9. Fotsis T., Pepper M., Adlercreutz H., et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90 (1993) 2690-2694
10. Wu P.C., Liu C.C., Chen C., et al. Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol 241 (2003) 63-69
11. Deutsch T.A., and Hughes W.F. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol 87 (1979) 536-540
12. Lipman R.M., Epstein R.J., and Hendricks R.L. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 110 (1992) 405-407
13. Joussen A.M., Kruse F.E., Volcker H.E., and Kirchhof B. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237 (1999) 920-927
14. Shi W., Gao H., Xie L., and Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47 (2006) 3339-3344
15. Bock F., König Y., Kruse F., Baier M., and Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246 (2008) 281-284
16. Kim R., and Toge T. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today 34 (2004) 293-303
17. Gasparini G., Longo R., Torino F., and Morabito A. Therapy of breast cancer with molecular targeting agents. Ann Oncol 16 (2005) S28-S36
18. Baker C.H., Kedar D., Mc Carty M.F., et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161 (2002) 929-938
19. Mahoney J.M., and Waterbury L.D. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 4 (1985) 531-535
20. Manzano R.P., Peyman G.A., Khan P., et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91 (2007) 804-807
21. Lu P., Li L., Mukaida N., and Zhang X. Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration. Cornea 26 (2007) 199-206
22. Philipp W., Speicher L., and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41 (2000) 2514-2522
23. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
24. Rowinsky E.K. Signal events: Cell signal transduction and inhibition in cancer. The Oncologist 8 (2003) 5-17
25. Baselga J., Albanell J., Molina M.A., and Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 28 (2001) 4-11
26. Lane H.A., Motoyama A.B., Beuvink I., and Hynes N.E. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 12 (2001) S21-S22
27. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
28. Mohsin S.K., Weiss H.L., Gutierrez M.C., et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23 (2005) 2460-2468
29. Mayfield S., Vaughn J.P., and Kute T.E. DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines. Breast Cancer Res Treat 70 (2001) 123-129
30. Nahta R., and Esteva Francisco J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 (2006) 123-138
31. Klos K.S., Zhou X., Lee S., et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98 (2003) 1377-1385
32. Guan H., Jia S.F., Zhou Z., Stewart J., and Kleinerman E.S. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res 11 (2005) 2008-2017
33. Izumi Y., Xu L., Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 21 (2002) 279-280
34. Niu G., and Carter W.B. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res 67 (2007) 1487-1493
35. Bahar I., Kaiserman I., Mc Allum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27 (2008) 142-147
36. Bahar I., Igor Kaiserman I., McAllum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33 (2008) 23-28
37. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12 (2006) 7242-7251
38. Moore S. Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs 23 (2007) S23-S30
39. Gan L., Fagerholm P., and Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82 (2004) 557-563